Autolus Therapeutics to Present Tumor Burden-Guided Dosing Data at SOHO 2024
Autolus Therapeutics to Present Tumor Burden-Guided Dosing Data at SOHO 2024
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting being held September 4-7, 2024 in Houston, Texas. These data demonstrate the rationale for tumor burden (TB)-guided dosing in adult patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL) by analyzing the impact of bone marrow (BM) blast percentage prior to lymphodepletion in patients treated with obe-cel in the FELIX Phase 1b/2 study.
Autolus Therapeutics plc（納斯達克：AUTL）是一家臨床階段的生物製藥公司，致力於開發下一代程序化T細胞療法，在2024年9月4日至7日於德克薩斯州休斯頓舉行的血液學腫瘤學協會（SOHO）年會上宣佈海報報告。這些數據通過分析注射obe-cel的FELIX Phase 1b/2研究中，在成人復發/難治性B細胞急性淋巴細胞白血病（r/r b-ALL）患者進行淋巴結脫敏前的骨髓（BM）爆發百分比的影響，展示了腫瘤負荷（TB）引導劑量的合理性。
譯文內容由第三人軟體翻譯。